Immune-related endocrine disorders in novel immune checkpoint inhibition therapy

Immune checkpoint inhibition against advance malignancies was named breakthrough discovery by the science magazine in 2013. In numerous clinical studies, monoclonal antibodies against the immune checkpoints, CTLA4, PD1 and PD1 ligand PDL1 have shown promising tumor response in different type of meta...

Descripción completa

Detalles Bibliográficos
Autor principal: Min, Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881952/
https://www.ncbi.nlm.nih.gov/pubmed/29623291
http://dx.doi.org/10.1016/j.gendis.2016.10.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881952/
https://www.ncbi.nlm.nih.gov/pubmed/29623291
http://dx.doi.org/10.1016/j.gendis.2016.10.002

Ejemplares similares